Spinocerebellar Ataxias Competitive Analysis Report 2021: Emerging Therapies and Key pharma players involved by DelveInsight

 Breaking News
  • No posts were found

Spinocerebellar Ataxias Competitive Analysis Report 2021: Emerging Therapies and Key pharma players involved by DelveInsight

March 04
13:09 2021
Spinocerebellar Ataxias Competitive Analysis Report 2021: Emerging Therapies and Key pharma players involved by DelveInsight

DelveInsight Business Research LLP
DelveInsight’s, “Spinocerebellar Ataxias – Pipeline Insights, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Spinocerebellar Ataxias pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s, Spinocerebellar Ataxias – Pipeline Insights, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Spinocerebellar Ataxias pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Symptoms

  • Gait ataxia and incoordination
  • Nystagmus/visual problems
  • Dysarthria
  • Extrapyramidal signs
  • Ophthalmoplegia
  • Cognitive impairment in specific SCAs

Click the link and get access to free sample pages of the report.

Diagnosis

A phenotype-first approach remains pertinent in molecular diagnosis of rare genetic disorders. Clinicians should also consider genetic testing for primary episodic ataxias (EA). Advances in next-generation sequencing (NGS) have facilitated further insights into the molecular causes of SCA. Exome sequencing identifies less classical phenotype–genotype correlations and detects new mutations in known cerebellar genes.

Treatment

Advancements in the understanding of pathophysiologic mechanisms facilitate the potential to find new therapeutic targets. Riluzole, a drug licensed for the treatment of ALS, was reconsidered for the treatment of patients with ataxia owing to its ability to inhibit presynaptic glutamate release and activate calcium-activated potassium channels.The anticonvulsant valproic acid has been proposed as a pharmacological treatment in SCA3/MJD for its neuroprotective properties as a pan-histone deacetylase inhibitor. Lithium carbonate was evaluated in 62 ambulatory patients with SCA3/MJD for 48 weeks, but no difference was seen in mean scores of the neurological scale for ataxia. Varenicline is a partial agonist of the α4β2 neuronal nicotinic acetylcholine receptor that is used to aid the cessation of smoking. Varenicline was anecdotally reported to have beneficial effects in patients with ataxia that were taking it as part of a smoking cessation programme. General supportive management options include physiotherapy, occupational therapy and speech therapy. Physiotherapy focused on improving gait, balance, coordination, posture and muscle strength is often recommended.

Spinocerebellar Ataxias Emerging Drugs Chapters

This segment of the Spinocerebellar Ataxias report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spinocerebellar Ataxias Emerging Drugs

KPS-0373 by Kissei Pharmaceutical

KPS-0373 is an l drug that is a TRH receptor agonist. It has recently completed Phase III trial of clinical study. It was originally developed by Kissei Pharmaceutical but now licensed to Shinogi.

Request for sample pages: https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-pipeline-insight

Table of contents:

1. Report Introduction

2. Spinocerebellar Ataxia

3. Spinocerebellar Ataxia Current Treatment Patterns

4. Spinocerebellar Ataxia- DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Spinocerebellar Ataxia Late Stage Products (Phase-III)

7. Spinocerebellar Ataxia Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Spinocerebellar Ataxia Discontinued Products

13. Spinocerebellar Ataxia Product Profiles

14. Spinocerebellar Ataxia Key Companies

15. Spinocerebellar Ataxia Key Products

16. Dormant and Discontinued Products

17. Spinocerebellar Ataxia Unmet Needs

18. Spinocerebellar Ataxia Future Perspectives

19. Spinocerebellar Ataxia Analyst Review  

20. Appendix

21. Report Methodology

Download report: https://www.delveinsight.com/report-store/spinocerebellar-ataxias-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/